Biotech investors are once again rotating aggressively into clinical-stage growth stories as a fresh wave of capital ...

Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging partnerships and a robust ...

Focused on immunology-based therapies for infectious diseases, this biotech company reported a notable insider sale in recent ...

Vir Biotechnology develops immunology-based therapies targeting infectious diseases through global partnerships and scientific innovation.

StrainX Bioworks, a synthetic biology and precision fermentation startup, has raised $13 million to advance its biotechnology platform. The company, with a team of over 100 experts, aims to scale ...

Microbial biotechnology is a dynamic field, The origins of microbiology can be traced back to the pioneering research by scientists such as Louis Pasteur and Robert Koch in the 19 th century. Within a ...

Discover the role of biotechnology in healthcare, medicine, and investment. Understand biotech processes, top companies, and ...

Research Alliance III follows a few months after Cormorant Asset Management priced a $150 million IPO for its own blank-check ...

Is VIR a good stock to buy? We came across a bullish thesis on Vir Biotechnology, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on VIR. Vir Biotechnology, ...

Vir Biotechnology develops immunology-based therapies for infectious diseases, backed by collaborations and a diversified ...